Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Cixutumumab |
Trade Name | |
Synonyms | IMC-A12 |
Drug Descriptions |
Cixutumumab (IMC-A12) is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (PMID: 29520435, PMID: 29909907). |
DrugClasses | IGF1R Antibody 8 |
CAS Registry Number | 947687-12-9 |
NCIT ID | C79828 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel | Bevacizumab Carboplatin Cixutumumab Paclitaxel | 0 | 0 |
Cetuximab + Cixutumumab | Cetuximab Cixutumumab | 0 | 0 |
Cixutumumab | Cixutumumab | 0 | 2 |
Cixutumumab + Everolimus + Octreotide acetate | Cixutumumab Everolimus Octreotide acetate | 0 | 0 |